Dorval Allison 4

What Happened
Dorval Allison, a director of Puma Biotechnology (PBYI), sold 11,610 shares in an open-market transaction on 2026-06-12 at a weighted average price of $7.20 for proceeds of approximately $83,579. The filing also reports an award of 27,000 restricted stock units (RSUs) on 2026-06-11 (reported $0.00 acquisition price) that vest subject to continued service.

Key Details

• Sale: 11,610 shares disposed on 2026-06-12; weighted average price $7.20; total proceeds ≈ $83,579. Sales executed in multiple transactions at prices ranging $6.98–$7.32 (filing offers to provide per-price breakdown on request).
• Grant: 27,000 RSUs granted 2026-06-11; reported acquisition price $0.00.
• 10b5-1 plan: Footnote notes a referenced 10b5-1(c) plan adopted 03-12-2025 (indicative of a preplanned sale schedule).
• Shares owned after the reported transactions: not specified on this Form 4.
• Filing: Form 4 filed 2026-06-15 for report period 2026-06-11 (no late-filing notation in the filing).

Context

• The 27,000 RSUs vest in full on the earlier of the one-year anniversary of the grant date and the date of the issuer's next annual shareholder meeting, subject to continued service (per footnote).
• The sale was executed under an open-market/plan framework (10b5-1 referenced), which often indicates a preplanned sale rather than a discretionary trade. Sales by directors can be routine and do not, by themselves, signal company outlook.